Quick Search


 

Result Summaries: abacavir/lamivudine/zidovudine

ViiV
Study ID
   Phase    Title Summary (Download)
111950_3 n\a Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure (0 citation(s)) Click here to download result summary.
112872_3 n\a HIV treatment and CVD events - Ingenix. Retrospective Database Analysis of Patients with Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events (0 citation(s)) Click here to download result summary.
112877_5 N/A Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (5 citation(s)) Click here to download result summary.
112878_5 N/A Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus (0 citation(s)) Click here to download result summary.
112879_2 N/A Incidence of abacavir hypersensitivity reactions in EuroSIDA (1 citation(s)) Click here to download result summary.
112885_3 N/A Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy (1 citation(s)) Click here to download result summary.
112887_3 N/A Studies using DAD - Effects of different interventions to improve ART-associated dyslipidemia (1 citation(s)) Click here to download result summary.
112889_1 N/A HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies (0 citation(s)) Click here to download result summary.
113039_3 N/A Studies using DAD - Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (1 citation(s)) Click here to download result summary.
113156_3 N/A Studies using the VA - Studies done under the Oversight Committee for the Evaluation of the metabolic complications of HAART (2 citation(s)) Click here to download result summary.
113329_3 n\a Lactic acid levels in children pre- and perinatally treated with antiretrovirals to prevent HIV transmission (Giaquinto; Hyperlactatemia in infants with in utero exposure to ZDV/3TC ) (2 citation(s)) Click here to download result summary.
113660 n\a TZV Epidemiology Program of HSR and Rechallenge HSR: VA (0 citation(s)) Click here to download result summary.
113671 n\a TZV Epidemiology Program of HSR and Rechallenge HSR: UHC (0 citation(s)) Click here to download result summary.
113761 n\a TZV Epidemiology Program of HSR and Rechallenge HSR: HIV Insight (0 citation(s)) Click here to download result summary.
113762 n\a TZV Epidemiology Program of HSR and Rechallenge HSR: CHORUS (0 citation(s)) Click here to download result summary.
AZL10001 Phase 1 An Evaluation of the Bioequivalence of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) Compared to ZIAGEN (abacavir) 300mg tablet, EPIVIR (lamivudine) 150mg tablet, and RETROVIR (zidovudine) 300mg tablet Administered Concurrently and the Effect of Food on Absorption i ... (1 citation(s)) Click here to download result summary.
AZL10002 Phase 1 An Evaluation of the Steady-State Pharmacokinetics of abacavir, lamivudine, and zidovudine following administration of a Combined Formulated Tablet (300/150/300mg abacavir/lamivudine/zidovudine) versus ZIAGEN (300mg abacavir) and COMBIVIR (150/300mg lamivudine/zidovudine) in Subjects with HIV-1 ... (1 citation(s)) Click here to download result summary.
AZL30002 Phase 3 A Phase IIIb, Randomised, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of a Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Versus Continued Antiretroviral Triple Therapy in HIV-1 Infected Subjects with Undetectable Plasma HIV-1 RNA Levels (TRIZAL) (3 citation(s)) Click here to download result summary.
AZL30004 Phase 3 A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability of TRIZIVIR plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for 24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ... (3 citation(s)) Click here to download result summary.
AZL30004_1 Phase 3 A Phase IIIb/IV, Randomised, Open-Label, Multicentre Study to Evaluate the Efficacy, Safety and Tolerability ofTRIZIVIR. plus Efavirenz (Quad) Over 72 Weeks Versus Quad Therapy for 48 Weeks Followed by TRIZIVIR Alone for24 Weeks Versus Quad Therapy for a minimum of 24 Weeks Followed by TRIZIVIR ... (3 citation(s)) Click here to download result summary.
AZL30006 phase 3 A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg twice daily or 700mg/100mg twice daily) When Used in Combination with a Zidovudine-containing Regimen (TRIZIVIR or COMBIVIR twice daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects. (1 citation(s)) Click here to download result summary.
AZL40001 Phase 4 An open-label, single arm, multicentre, pilot phase IV study to evaluate the efficacy and safety of a potent combination therapy (Trizivir + Efavirenz) in antiretroviral nave adults with a CD4+ cell count <200mm3 over a 48-week treatment period (TETRA Trizivir Efavirenz TReAtment) (2 citation(s)) Click here to download result summary.
AZLF3002 Phase 3 Multicentre, open-label, pilot study to evaluate the efficacy and safety of a triple therapy combining AZT/3TC/ABC as a combined tablet of Trizivir, in HIV-infected patients with an undetectable viral load after quadruple therapy (COM, ABC, EFV) during CNAF 3008 study (La Francilienne). (0 citation(s)) Click here to download result summary.
AZLF3004 Phase 3 An Open-label study to evaluate long-term (48 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF3004-Trisud (1 citation(s)) Click here to download result summary.
CNAF3016 Phase 3 A Pilot Study to assess the Efficacy and Safety of a quadritherapy with Combivir, Abacavir, Nelfinavir switching from week 16 to (TZV), Nelfinavir for Antiretroviral Therapy in HIV-infected Naive Subjects with a viral load > 50 000 copies/mL (0 citation(s)) Click here to download result summary.
COL30281 Phase 3 An open label, randomised study, to evaluate the safety and efficacy of Combivir plus abacavir (Ziagen) versus Combivir plus Viracept, in HIV-1 infected antiretroviral therapy naive adults with a plasma HIV-1 RNA between 1000 and 500,000 copies /mL. (1 citation(s)) Click here to download result summary.
COL30336 Phase 4 A Phase IV, Open-Label, Multicenter Study of the Efficacy and Safety of Quadruple Combination Antiretroviral Therapy with COMBIVIR (Lamivudine 150mg/Zidovudine 300mg) BID, ZIAGEN (Abacavir) 300mg BID, and SUSTIVA (Efavirenz) 600mg QD for 24 Weeks, Followed by Therapy with the Triple Nucleoside C ... (3 citation(s)) Click here to download result summary.
COL30441 Phase 3 A Pilot, Multicentre Study to Evaluate the Efficacy and Safety of an Antiretroviral Therapy with Trizivir [abacavir, lamivudine, zidovudine] and Efavirenz after a 14-week Structured Antiretroviral Treatment Interruption, in HIV-1 Infected Subjects with a Viral Load > 5000 copies/mL… (2 citation(s)) Click here to download result summary.
COL30470 Phase 4 A Pilot, Randomised, Open-Label, Monocenter Study to Evaluate the Safety and Efficacy of a Quadruple Combination Therapy of Triple Combination Tablet (Trizivir) [abacavir, lamivudine, zidovudine] Plus Saquinavir-SGC/Ritonavir Versus Triple Combination Therapy of Combivir Plus Saquinavir-SGC/Rito ... (1 citation(s)) Click here to download result summary.
COL30494 Phase 4 An Open-Label Multicentre Study to Evaluate the Adherence to, General Satisfaction and Quality of Life After 24 Weeks Therapy With a Triple Combination tablet (TRIZIVIR™) [Abacavir, Lamivudine, and Zidovudine] in HIV-1 Infected Subjects With Undetectable Plasma HIV-1 RNA Levels (2 citation(s)) Click here to download result summary.
COL30528 Phase 3 An open label study to evaluate long term (96 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF 3006 – Suburbs 2 (1 citation(s)) Click here to download result summary.
COL30574 Phase 3 A phase IIIB, non-comparative, single arm, open-label, multicenter study on antiviral efficacy and safety of the approach “Induction- Maintenance” in patients with HIV-1 infection naïve to antiretroviral therapy. A 72-week study on the scheme: induction with TRIZIVIR® + SUSTIVA® or COMBIVIR® + SUSTIVA® OR COM (0 citation(s)) Click here to download result summary.
COL40263 phase 3 A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir in Combination with Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naïve Subjects with Viral Loads ?30,000 copies/mL (7 citation(s)) Click here to download result summary.
ESS 30005 Phase 4 A phase IV, open-label, multicenter study of treatment with TRIZIVIR (abacavir 300mg/lamivudine 150mg/zidovudine 300mg) twice daily and tenofovir 300mg once-daily for 48 weeks in HIV-infected subjects experiencing early virologic failure (ZIAGEN Intensification Protocol) (2 citation(s)) Click here to download result summary.
ESS40005 Phase 3 A Phase IIIB Randomized, Multi-center Study of the Efficacy and Safety of COMBIVIR 1 Tablet PO BID Plus ZIAGEN 300mg PO BID Versus an Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet PO BID, Administered for 24 Weeks in Subjects With HIV-1 Infection (2 citation(s)) Click here to download result summary.
ESS40013 Phase 4 A Phase IV Multi-center Study of the Efficacy and Safety of 48-Week Induction Treatment with TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg Combination Tablet BID) + Efavirenz (600mg QD) Followed by 48-Week Randomized, Open-Label, Maintenance Treatment with TRIZIVIR… (2 citation(s)) Click here to download result summary.
NZTA4006 Phase 3 A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virologic Outcomes, Adherence, Immunologic Outcome, and Health Outcomes in HIV-Infected Subjects from Under-Represented Populations Treated with Triple Nucleoside Therapy (COMBIVIR, Lamivudine 150mg/Zidovudi ... (1 citation(s)) Click here to download result summary.